Julia H Miao

Dr. Julia H Miao


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JBJoshua Brooks
Joshua Brooks
OMOla A. E. Mohamed
Ola A. E. Mohamed
JMJulia H Miao
Julia H Miao
HMHaidy Megahed
Haidy Megahed
AHAhmed Hamimi
Ahmed Hamimi
Cancer-associated thrombosis (CAT) is a leading cause of morbidity and mortality in patients with malignancy, yet its imaging manifestations extend far beyond the conventional diagnosis of deep vein thrombosis and pulmonary embolism. This comprehensive review examines the full spectrum of CAT as encountered by radiologists, from routine venous thromboembolism to unusual-site thromboses, arterial thromboembolic events, catheter-related complications, and endovascular management strategies. Patients with cancer face a four- to seven-fold increased risk of venous thromboembolism compared with the general population, and arterial thromboembolism occurs at more than twice the expected rate, particularly within the first six months following cancer diagnosis. The radiologist’s role spans detection, characterization, and therapeutic guidance across multiple vascular territories. Key diagnostic challenges addressed include the distinction between bland and tumor thrombus—a determination with direct implications for TNM staging, surgical planning, and systemic therapy selection—and the recognition of incidental thromboembolism, which carries prognostic weight equivalent to symptomatic events and warrants similar clinical management. Emerging applications of diffusion-weighted MRI, contrast-enhanced ultrasound, and FDG-PET/CT provide a multiparametric toolkit for thrombus characterization, while artificial intelligence and machine learning show promise for improving patient selection and reducing unnecessary imaging. The expanding recognition of cancer-associated arterial disease, including cerebrovascular, coronary, and peripheral arterial events, requires that cardiovascular structures receive systematic attention on routine oncologic imaging. Interventional radiology contributes actively to CAT management through inferior vena cava filtration, catheter-directed thrombolysis, and thrombolytic-sparing mechanical thrombectomy, the latter being particularly relevant in oncology patients with elevated bleeding risk. Conclusions: Realizing the full potential of imaging in CAT requires not only technical proficiency with individual modalities but a synthesized, oncology-informed interpretive approach that incorporates the patient’s treatment history, biomarker status, and thrombotic risk profile at the time of image interpretation, positioning the radiologist as a central rather than peripheral figure in oncologic care.

25 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JMJulia H Miao
Julia H Miao
OMOla A. E. Mohamed
Ola A. E. Mohamed
CSChristopher Straus
Christopher Straus
VPVanessa Peters
Vanessa Peters
EMEmily Miller
Emily Miller
AHAhmed Hamimi
Ahmed Hamimi
Artificial intelligence (AI) has generated considerable excitement in radiology, with claims of transformative improvements in diagnostic accuracy, workflow efficiency, and clinical decision support. However, a critical gap persists between AI’s theoretical promise and its real-world performance, particularly in complex, high-stakes scenarios such as cancer-associated thromboembolism (CAT). CAT is a leading cause of morbidity and mortality in oncology patients, yet it remains underdiagnosed on routine imaging. This paper provides a general radiology critique of current AI applications, then narrows focus to CAT management. This review additionally evaluates AI’s role in incidental pulmonary embolism detection, risk stratification, and treatment decision support. While AI demonstrates sensitivity gains, it faces substantial limitations: data heterogeneity, lack of prospective validation, poor generalizability across cancer subtypes, and integration challenges with clinical workflows. Therefore, AI is not yet a reliable standalone tool for CAT management, but may serve as an adjunct if clinically validated, explainable, and embedded within multidisciplinary frameworks.